Erbb4 receptor-specific neuregulin related ligands and uses therefor
CA 2296807 C · Owner: Zhang, Dong-Xiao · Inventors: Godowski, Paul J.; Zhang, Dong-Xiao; Mark, Melanie R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain a transmembrane domain and , a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences recombinant host cells transformed with vectors and methods for the , recombinant production for the novel NRG3s are also within the scope of the invention.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 30, 1998 and granted August 23, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 30, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 30, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.